BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, is leaving the Company to become the Chief Executive Officer of Viatris (Nasdaq: VTRS), a large, global healthcare pharmaceutical company. Scott will remain connected to BioAtla, serving as a member of the Board of Directors.
BioAtla is deeply grateful for the contributions Scott has made since joining the company in 2018. His wealth of experience in biotechnology and pharmaceutical executive leadership roles has been instrumental in the expansion of the Company’s operations and the progress of its pipeline and clinical programs. With his expertise, knowledge, vision, energy and passion, the company is lucky to still have Scott as a Board member, and wishes him all the best in his new venture.
Working alongside the dedicated team at BioAtla has been a true privilege. I am immensely proud of all that the Company has achieved and continues to achieve in its mission to improve the lives of patients. I am looking forward to maintaining my relationship with BioAtla as a Board member and am enthusiastic about the evolving CAB product portfolio.
About BioAtla®, Inc.
BioAtla is a global biotechnology company that develops novel, conditionally active monoclonal and bispecific antibodies and other protein therapeutic product candidates. Their advanced Conditionally Active Biologics (CAB) technology is designed to provide greater efficacy with lower toxicity and more cost-effective manufacturing than traditional antibodies. With 704 patents (430 issued, 5 allowed, and 269 pending) in all major markets, BioAtla is proud to have two first-in-class CAB programs currently in Phase 2 clinical testing. These include mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate, and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate. In addition, the company’s Phase 1 stage CAB-CTLA-4 antibody, BA3071, is a state-of-the-art CTLA-4 inhibitor designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors. Finally, BioAtla’s first clinical stage bispecific antibody, BA3182, targets EpCAM while engaging human CD3 expressing T cells.